Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

Explore the transformation of weight-loss drugs with the rise of GLP-1 pills, the impact of telehealth, and consumer-driven ...

Health‑advertising researcher Erin Willis at the University of Colorado-Boulder said consumers are now bombarded with GLP-1 ...

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.

China will begin reimbursing Eli Lilly’s blockbuster drug Mounjaro for type 2 diabetes from January 1, widening access to the therapy in one of the world’s largest healthcare markets Placement on ...

US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.

While the drugs have become spectacularly popular, their high prices, along with spotty insurance coverage, have left them ...

Earlier this week, the FDA approved Eli Lilly and Company’s LLY rival Novo Nordisk’s NVO oral version of the obesity drug ...

Fewer people in the U.S. are drinking alcohol these days. The holidays have long been a season to overindulge, whether that means too many glasses of wine or too many cookies. But this year may be ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

With the oral version of the slimming drug, the Danish company aims to regain ground, win over millions of patients and strengthen its position against competitors such as Eli Lilly.

In a new clinical trial, people with obesity and knee osteoarthritis who took an experimental drug from Eli Lilly lost large ...